Berkshire Hathaway To Buy OxyChem For $9.7 Bln Cash From Occidental Petroleum

Berkshire Hathaway Inc. (BRK) has agreed to acquire OxyChem, the chemical business of Occidental Petroleum Corporation (OXY), for $9.7 billion in cash. This strategic acquisition, anticipated to close in the fourth quarter of 2025, will integrate OxyChem's critical commodity chemical operations, which are essential for applications in water treatment, pharmaceuticals, and healthcare, into Berkshire's diverse portfolio.

Analysis

Berkshire Hathaway (BRK) has executed a definitive agreement to acquire OxyChem, the chemical division of Occidental Petroleum (OXY), for $9.7 billion in an all-cash transaction. The deal, which has a notably long closing timeline projected for the fourth quarter of 2025, represents a significant strategic move for both entities. For Berkshire Hathaway, this acquisition aligns with its core strategy of deploying its substantial cash reserves into businesses with durable, long-term value; OxyChem's focus on commodity chemicals essential for defensive sectors like water treatment, pharmaceuticals, and healthcare fits this profile. The market's positive sentiment for BRK (score: 0.6) reflects approval of this expansion into the commodity chemicals space. For Occidental Petroleum, this divestiture provides a substantial cash infusion, which could be used for deleveraging or reinvestment into its core operations. The neutral-to-positive sentiment for OXY (score: 0.5) suggests the market views this as a logical, albeit not transformative, restructuring step.

Key Decisions for Investors

• Investors in Berkshire Hathaway should view this acquisition as a classic deployment of capital into a stable, cash-generative industrial business, reinforcing the company's long-term investment thesis.
• For Occidental Petroleum stakeholders, the key catalyst to monitor will be management's stated use for the $9.7 billion in cash proceeds, which will likely be directed towards debt reduction or reinvestment in core energy assets.
• Given the extended closing timeline of Q4 2025, any direct valuation impact is deferred, and investors should focus on the long-term strategic realignment for both companies rather than near-term M&A arbitrage.